TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02929667
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 6 weeks titration.
Study: NCT01070498
Drug: Trichuris suis ova (TSO)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive TSO every other week for 3 months. The dose will depend on the age of the subject and vary between 100 and 2500 eggs. TSO will be administered orally as a suspension in single dose vials prepared by Ovamed GmbH, a company not directly involved in the study.
Study: NCT03607487
Drug: INCB054707
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB054707 tablet administered orally once daily at the protocol-defined dose.
Study: NCT03607487
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet administered orally once daily.
Study: NCT04170348
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to receive once monthly oral bolus of vitamin D3, will receive placebo on all other days of the month.
Study: NCT04555577
Drug: Peposertib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT03895996
Drug: AVT001
Approvals — FDA: no, EMA: no, PMDA: no
Description: autologous dendritic cell therapy
Study: NCT03507257
Drug: Fluorodeoxyglucose
Normalized name: fluorodeoxyglucose F18
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive a single bolus intravenous injection of approximately 5 mCi (+/- 10%, 0.5 mCi) of fluorodeoxyglucose. At approximately 30 minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.
Study: NCT02023567
Drug: SSRIs
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluoxertine hydrochloride 20-60mg/day, paroxetine hydrochloride 20-60mg/day, sertraline hydrochloride 50-200mg/day, citalopram 20-60mg/day, escitalopram 10-20mg/day, fluvoxamine 50-300mg/day
Study: NCT01886313
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02837965
Drug: treatment with topical superpotent corticosteroid therapy
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05113420
Drug: Troxevasin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troxerutin
Study: NCT01880502
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo single dose administration
Study: NCT01567956
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg inert substances modified release tablets, 500 mg bid; treatment duration 8 weeks
Study: NCT01179490
Drug: SyB L-0501
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: SyB L-0501 (150 mg/m2/day) will be administered by intravenous drip infusion for 60 min for 2 consecutive days and the course will be observed for the next 26 days. This is taken as one cycle and administration is repeated for 2-9 cycles (when a plateau is not reached after nine cycles, administration of up to an additional three cycles for a maximum of 12 cycles is possible).
Study: NCT01179490
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone will be administered (60 mg/m2/day) orally for 4 consecutive days and the course will be observed for the next 24 days.
Study: NCT00683995
Drug: KW-2246 (fentanyl citrate)
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: KW-2246 (fentanyl citrate)
Study: NCT00005073
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02761980
Drug: Ibuprofen 250 mg / Acetaminophen 500 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 250 mg / Acetaminophen 500 mg
Study: NCT02761980
Drug: Ibuprofen 250 mg
Normalized name: ibuprofen 250 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 250 mg
Study: NCT02761980
Drug: Acetaminophen 500 mg
Normalized name: acetaminophen 500 MG
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 APAP 500 mg caplet
Study: NCT03423667
Drug: Lactose powder
Normalized name: Lactose Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator.
Study: NCT04076059
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT04076059
Drug: Androgen deprivation therapy (ADT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants were required to maintain ADT during study treatment, either using luteinizing hormone-releasing hormone (LHRH) agonist/antagonist or having a history of bilateral orchiectomy.
Study: NCT02146430
Drug: DS-5565
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-5565 15 mg tablet for oral administration
Study: NCT02146430
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet (matching DS-5565) for oral administration
Study: NCT04625725
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose (× 2IM injections) of saline placebo on parent study Day 1.
Study: NCT04578158
Drug: Standard COVID-19 care
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive standard covid-19 care as per the hospital/physician guidelines
Study: NCT02677896
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01469364
Drug: Aztreonam Lysine for Inhalation (AZLI)
Normalized name: aztreonam Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention will involve open label treatment with AZLI inhaled 75mg TID self-administered intermittently for 28 days on study drug and 28 days off study drug over a study period of 5 consecutive months (on/off/on/off/on AZLI)
Study: NCT00071097
Drug: TMC114/rtv
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800mg TMC114/100mg rtv once daily
Study: NCT00071097
Drug: TMC114/rtv
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg TMC114/100mg rtv both twice daily
Study: NCT00071097
Drug: TMC114/rtv
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg TMC114/100mg rtv once daily
Study: NCT00071097
Drug: TMC114/rtv
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mg TMC114/100mg rtv twice daily
Study: NCT02592161
Drug: Experimental
Normalized name: WA-001 Experimental Soil Surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug : Granules, Chung A Won 3g (Eucommiaceae, Psoralea corylifolia, Walnut, Ginger) Three times a day, oral administration for 24weeks~Reference drug : Granules, Placebo 3g (Lactose hydrate, Corn starch, Caramel pigment)~Three times a day, oral administration for 24weeks
Study: NCT01893905
Drug: CS+SG
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin sulfate+glucosamine sulfate orally administered once a day for 24 weeks.
Study: NCT04233866
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01893905
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of chondroitin sulfate+glucosamine sulfate orally administered once a day for 24 weeks.
Study: NCT04233866
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04233866
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00316745
Drug: Campto, Topotesin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/m2, IV (in the vein) on day 1,15 of each cycle.
Study: NCT00316745
Drug: Isovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-leucovorin (200mg/m2) Day 1, 15
Study: NCT04533022
Drug: C21
Normalized name: C18-C21 alkane
Approvals — FDA: no, EMA: no, PMDA: no
Description: C21 b.i.d.
Study: NCT02441972
Drug: 18F-Al-NOTA-PRGD2 PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F-Al-NOTA-PRGD2(PET imaging agent) given by vein before PET scans.Perform PET/CT for each enrolled volunteer or patient at 60-90min.
Study: NCT01064349
Drug: Anti-erbB2 therapy as part of a treatment regimen for either brain metastases or primary breast cancer
Normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab or Lapatinib
Study: NCT03801876
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folinic acid, flurouracil and oxaliplatin
Study: NCT03801876
Drug: CAPOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine combined with oxaliplatin
Study: NCT03801876
Drug: 5FU
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy
Study: NCT01010178
Drug: Macrolid, Theophylline, Inhaler Corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: we have no permission to include them in detail because of privacy policy of mentioned journal for publication
Study: NCT00354744
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Age based dosage: ≥ 3 years 1200 mg/m2, \<3 years 40 mg/kg.~Day 1 of weeks 7, 11, 15, 28, 32, 35, 38, 41 and 44.~Given IV
Study: NCT00354744
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Age based dosage: ≥ 1 year: 37.5mg/m²/day, \< 1 year: treat with 50% doses calculated on a m2 basis. Total dose 75 mg/m².~Days 1 and 2 of weeks 7, 11, 15, 28 and 32.~Given IV
Study: NCT02658825
Drug: Placebo (Matching with Moxifloxacin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo (matching with Moxifloxacin) tablet orally once on Day 1 of Panel 2.
Study: NCT00989352
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3g/m² i.v. max. 9 times
Study: NCT02236715
Drug: Atrovent®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01762748
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule with 200 mg lyophilized S. boulardii-17 (about 4x108 cells), 6 mg sucrose and 2.4 mg magnesium stearate (Floratil®).
Study: NCT01544283
Drug: Synera® (lidocaine 70 mg and tetracaine 70 mg) topical patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synera consists of a thin, uniform layer of a local anesthetic formulation with an integrated, oxygen-activated heating component that is intended to enhance the delivery of the local anesthetics. The drug formulation is an emulsion in which the oil phase is a eutectic mixture of lidocaine 70 mg and tetracaine 70 mg. The surface area of the entire Synera patch is approximately 50 cm2, 10 cm2 of which is active. The 40 cm2 perimeter is a medical grade adhesive. The Synera patches used in this study are the commercially available form.
Study: NCT01112358
Drug: r-FSH
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-FSH will be administered as specified in the arm description.
Study: NCT01112358
Drug: r-hLH
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-hLH will be administered as specified in the arm description.
Study: NCT01208012
Drug: Victoza®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients taking Metformin at individual dose and Liraglutide 0.6 mg once daily for the 1st week, 1.2 mg daily for another 5 weeks, 1.8 mg daily for another 6 weeks. When arrived at the dosage of 1.8 mg daily and the dose is not tolerated by the patient, the dose of Liraglutide can be decreased.Liraglutide is injected in the subcutaneous tissue once daily
Study: NCT01112358
Drug: r-hCG
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-hCG will be administered as specified in the arm description.
Study: NCT01337700
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be given placebo tablets at dosing corresponding to the fixed schedule between 12.5mg and 100mg.
Study: NCT00799383
Drug: Calcium and Vitamin D
Normalized name: Wellesse Calcium and Vitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium carbonate 625mg and vitamin D 200IU will be administered, orally, twice a day for a nine-month period.
Study: NCT01234285
Drug: heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous heparin titrated to an aPTT of 40-50 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
Study: NCT01234285
Drug: heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous heparin titrated to an aPTT of 50-60 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
Study: NCT01234285
Drug: heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous heparin titrated to an aPTT of 40-45 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
Study: NCT01234285
Drug: heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5000 units subcutaneously three times a day, starting within 24 hours of ICU admission up to 6 days.
Study: NCT04670432
Drug: Hydroxyethylrutoside
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg film-coated tablet
Study: NCT00424489
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01140893
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00345410
Drug: AVE1625 B
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03868709
Drug: Placebo inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhalation is administered by inhalation (water for injection 0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygendriven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
Study: NCT01948297
Drug: Debio1347 (CH5183284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Debio1347 (CH5183284) tablets for oral administration
Study: NCT01166542
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01346852
Drug: Asthma treatment with an asthma-related medication and at least one asthma controller medication
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: participants with an asthma diagnosis who also had at least one dispensing event of an asthma-related medication and had at least one asthma controller medication (inhaled corticosteroids containing inhalers, methylxanthines, leukotriene receptor antagonists, cromolyn sodium) or albuterol.
Study: NCT01005823
Drug: LEO 29102 cream
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice daily application for 7 days
Study: NCT01005823
Drug: LEO 29102 placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEO 29102 placebo cream
Study: NCT00639678
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg intravenously, double dose (day 0 and 14), Group 3
Study: NCT00639678
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg placebo, single dose (day 0), Group 4
Study: NCT01313793
Drug: Treatment A-B
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects to receive 3 X 15 mg tablets of the clinical formulation in first period then 1 x 45 mg tablet of the commericializable formulation in 2nd period.
Study: NCT01313793
Drug: Treatment B-A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects to receive 1 x 45 mg tablet of the commericializable formulation in first period then 3X 15 mg tablets of the clinical formulation in 2nd period.
Study: NCT00543478
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250mg, twice a day in sachets, for 8 weeks
Study: NCT00543478
Drug: Methyl cellulose powder (low viscosity)
Normalized name: cellulose Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice a day sachets for 10 weeks
Study: NCT01988883
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locking gelatin capsules filled with microcrystalline cellulose
Study: NCT02902055
Drug: Neuromuscular Blocking Agents
Normalized name: NEUROMUSCULAR BLOCKING AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromuscular blockae
Study: NCT02902055
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01725451
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered topically to axillae
Study: NCT03295721
Drug: HTX-011
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTX 011 (bupivacaine/meloxicam), 60 mg/1.8 mg by instillation
Study: NCT03295721
Drug: Saline Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo by instillation
Study: NCT01520051
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 monthly intravenous infusions with saline
Study: NCT01920737
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01920737
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01920737
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01124851
Drug: ABT-652
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: See arm description for details
Study: NCT04360629
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline will be given through central vein
Study: NCT00770510
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
Study: NCT02834611
Drug: Ceramide NanoLiposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of Ceramide NanoLiposome
Study: NCT02808208
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-mL of Lactated Ringers solution topical application to the surface of the outflow vein (right next to the fistula) over a five-minute period.
Study: NCT00971893
Drug: Oral Methylprednisolone Tablets
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Methylprednisolone tablets given as per locally approved prescribing information
Study: NCT00571428
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhalation solution (citrate buffered 0.9% saline solution) once a day
Study: NCT00526968
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule, single oral dose
Study: NCT01252069
Drug: PGL4001, placebo, drug free period
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets) during 3 periods each ending with a drug free period until return of menses.
Study: NCT01252069
Drug: PGL4001, progestin, drug free period
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of progestin Norethisterone acetate 10mg once daily (oral tablets) during 3 periods each ending with a drug free period until return of menses.
Study: NCT02192346
Drug: 2.4 mg/kg α-TEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive oral α-TEA 2.4 mg/kg daily for the first 14 days of a 28 day cycle.
Study: NCT02192346
Drug: 4.8 mg/kg α-TEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive oral α-TEA 4.8 mg/kg daily for the first 14 days of a 28 day cycle.
Study: NCT02192346
Drug: 9.6 mg/kg α-TEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive oral α-TEA 9.6 mg/kg daily for the first 14 days of a 28 day cycle.
Study: NCT02192346
Drug: 12 mg/kg α-TEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive oral α-TEA 12 mg/kg daily for the first 14 days of a 28 day cycle.
Study: NCT02192346
Drug: 16.8 mg/kg α-TEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive oral α-TEA 16.8 mg/kg daily for the first 14 days of a 28 day cycle.
Study: NCT02192346
Drug: 19.2 mg/kg α-TEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive oral α-TEA 19.2 mg/kg daily for the first 14 days of a 28 day cycle.
Study: NCT02192346
Drug: 22.3 mg/kg α-TEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive oral α-TEA 22.3 mg/kg daily for the first 14 days of a 28 day cycle.
Study: NCT02192346
Drug: 26.8 mg/kg α-TEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive oral α-TEA 26.8 mg/kg daily for the first 14 days of a 28 day cycle.
Study: NCT02778919
Drug: KLH-2109
Normalized name: LINZAGOLIX CHOLINE 1 kg in 1 kg POWDER [KLH-2109 Choline]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02778919
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04449484
Drug: MEDI1341
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion over 60 minutes
Study: NCT01626456
Drug: ALKS 9072, Low
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM injection, given monthly
Study: NCT01373970
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, one tablet daily for 12 weeks
Study: NCT01626456
Drug: ALKS 9072, High
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM injection, given monthly
Study: NCT00813306
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution, 1 single dose
Study: NCT01652079
Drug: CRLX101
Approvals — FDA: no, EMA: no, PMDA: no
Description: q 14 days
Study: NCT03316729
Drug: DS-9231
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-9231 in saline solution for intravenous infusion